Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and fracture risk. Estrogen deficiency is its principal cause in postmenopausal women, sex steroid deficiency is a common cause in men, and several fracture-preventing drugs act on hormonal pathways, although the most widely prescribed agents, the bisphosphonates and denosumab, do not. This narrative review summarizes the randomized trial evidence for estrogen, selective estrogen receptor modulators, the tissue-selective estrogen complex, tibolone, progestogens, parathyroid hormone receptor agonists, and androgens, and for the iatrogenic hypogonadal states produced by androgen deprivation therapy, aromatase inhibitors, gonadotropin-releasing hormone agonists, and glucocorticoids. PubMed, Embase, and the Cochrane Library were searched to September 2026, with priority given to randomized trials with fracture endpoints. Estrogen reduces vertebral and hip fracture in women recruited without regard to bone mineral density, and the benefit ends when treatment ends. Parathyroid hormone receptor agonists produce the largest early reduction in vertebral fracture of any hormonal agent, and the gain is lost unless an antiresorptive drug follows. Testosterone raises bone mineral density in older men but did not reduce fracture in the one adequately powered randomized trial, in which fracture incidence was higher on treatment than on placebo. Hormonal agents are therefore selected for their extraskeletal profile or to correct a hormonal deficit, alongside rather than in place of bisphosphonates, denosumab, and romosozumab. Implications for fracture liaison, perioperative planning, and implant fixation are discussed, and the open questions are stated as specific comparisons.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-16
DOI
https://doi.org/10.3390/jcm15228962
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention

Georgi Raykov, Dimitar Tenev, Nikolay Cherkezov, Nikolay Dimitrov et al.
Journal of Clinical Medicine
Bone health and osteoporosis research
article

Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention

Georgi Raykov, Dimitar Tenev, Nikolay Cherkezov, Nikolay Dimitrov, Georgi Enev
article en

Abstract

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and fracture risk. Estrogen deficiency is its principal cause in postmenopausal women, sex steroid deficiency is a common cause in men, and several fracture-preventing drugs act on hormonal pathways, although the most widely prescribed agents, the bisphosphonates and denosumab, do not. This narrative review summarizes the randomized trial evidence for estrogen, selective estrogen receptor modulators, the tissue-selective estrogen complex, tibolone, progestogens, parathyroid hormone receptor agonists, and androgens, and for the iatrogenic hypogonadal states produced by androgen deprivation therapy, aromatase inhibitors, gonadotropin-releasing hormone agonists, and glucocorticoids. PubMed, Embase, and the Cochrane Library were searched to September 2026, with priority given to randomized trials with fracture endpoints. Estrogen reduces vertebral and hip fracture in women recruited without regard to bone mineral density, and the benefit ends when treatment ends. Parathyroid hormone receptor agonists produce the largest early reduction in vertebral fracture of any hormonal agent, and the gain is lost unless an antiresorptive drug follows. Testosterone raises bone mineral density in older men but did not reduce fracture in the one adequately powered randomized trial, in which fracture incidence was higher on treatment than on placebo. Hormonal agents are therefore selected for their extraskeletal profile or to correct a hormonal deficit, alongside rather than in place of bisphosphonates, denosumab, and romosozumab. Implications for fracture liaison, perioperative planning, and implant fixation are discussed, and the open questions are stated as specific comparisons.

Journal of Clinical MedicineVol. 15(22)
Medical University of Sofia (BG), University Hospital of Zurich (CH), Klinik Sonnenhof (CH)
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon